Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- Clinical Study Details
A clinical trial to look at the long-term safety and effects of satralizumab in people with neuromyelitis optica spectrum disorder.
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Autoimmune Disorder Neuromyelitis optica spectrum disorder (NMOSD)
Study results
LPS WN42349 SAkuraMoon Final Results January 2025 English
(PDF, 0.3 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Bulgaria Bulgarian
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Canada French
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Croatia Croatian
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Germany German
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Hungary Hungarian
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Italy Italian
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Japan Japanese
(PDF, 0.5 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Korea Korean
(PDF, 0.6 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Malaysia Malay
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Poland Polish
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Romania Romanian
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Spain Spanish
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Taiwan Chinese
(PDF, 0.5 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Turkey Turkish
(PDF, 0.4 MB)
LPS WN42349 SAkuraMoon Final Results January 2025 Ukraine Ukrainian
(PDF, 0.4 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com